Highlights
==========

-   Level of cortisol may have a role in the outcomes of COVID-19 patients.

-   A positive correlation between cortisol and hospital anxiety and depression scale (HADS) score.

-   Higher score of HADS in non-survival compared with surviving patients.

Plain Language Summary
======================

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a wide range of disease severity among the patients. Prior studies have demonstrated that psychological stress plays a vital role in the vulnerability, severity, and recurrence of acute respiratory infection. Cortisol has been implicated as the cause of a wide range of mental and physical health outcomes. However, the impact of cortisol on outcomes in patients with Coronavirus Disease 2019 (Covid-19) is not clear. We found that the levels of cortisol in patients who died of Covid-19 were significantly higher in comparison with surviving patients. We also found that the cortisol level was correlated with the anxiety and depression levels.

1.. Introduction
================

The novel coronavirus has a wide range of disease severity among the patients. The Coronavirus Disease 2019 (COVID-19) causes viral damage to the cells and provokes a reactive storm of inflammation resulting in the multi-organ injury ([@B1]). Prior studies have demonstrated that psychological stress plays a vital role in the vulnerability, severity, and recurrence of acute respiratory infections ([@B4]; [@B18]). Stressful life events and perceived stress during the life lead to activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis, as well as the Autonomic Nervous System (ANS) ([@B14]; [@B17]). As a result of HPA activation, Corticotropin-Releasing Hormone (CRH), cortisol, epinephrine, and norepinephrine levels increase in the serum ([@B6]).

An increase in stress hormones exaggerates the inflammatory responses by suppressing the humoral and cellular immune system and altering the balance of pro-inflammatory cytokines ([@B3]; [@B6]). Recent studies have indicated changes in immune functions in patients with COVID-19 ([@B15]). We hypothesized that any lifetime stressful event in COVID-19 patients can be correlated with the severity of their illness. In this study, we evaluated the stress and anxiety during the lifetime of the COVID-19 patients and measured their serum cortisol levels to find any correlation between these factors and their outcomes.

2.. Methods
===========

This cross-sectional study was conducted on patients with a confirmed diagnosis of COVID-19 in a university-affiliated referral hospital in Tehran, Iran during March 2020. The inclusion criteria were the age of over 18 years, the onset of the illness within seven days of first symptoms, and mild to moderate COVID-19 based on the results of the Chest CT-Scan (Total CT Score \< 10) ([@B10]). The exclusion criteria were current use of corticosteroids, history of primary or secondary hypercortisolism or hypercortisolism, pregnancy, and no to consent to participate in the study. Informed consent was obtained from all participants and the complete medical history, clinical and biochemical evaluation, and cortisol measurement on the days of admission were recorded. We used the Persian version of the Hospital Anxiety and Depression Scale (HADS) to facilitate the early identification of both anxiety and depression simultaneously ([@B8]).

The HADS is a scale of 14 items, of which seven items are related to anxiety, and seven are related to depression. Each item on the questionnaire is scored from 0--3, which means that a person can score between 0 and 21 for either anxiety or depression. A score of 11 or higher demonstrates the probable presence (abnormal) of the mood disorder ([@B16]).

2.1.. Statistical analysis
--------------------------

SSPS version 16.0 (SPSS, Inc., Chicago, IL, USA) was used for data analysis. A Chi-square test was applied for demographic variables, and the independent t-test was used to compare numeric data. To assess the differences between the surviving and dead patients in cortisol level and HADS score, we performed a Two-Way Analysis Of Variance (ANOVA) using the factors "outcome" and "comorbidity". A correlation between HADS score and serum levels of cortisol was assessed by the Pearson correlation test and the results were presented as the Mean±Standard Deviation (SD). A P-value \< 0.05 was considered significant.

3.. Results
===========

A total of 30 patients with COVID-19, 17 (56.7%) males and 13 (43.3%) females, were enrolled in this research. The mean age of the patients was 53.41±18.88 years. The serum level of cortisol and HADS score in COVID-19 patients are depicted in [Table 1](#T1){ref-type="table"}. Analysis of the HADS score and cortisol revealed a higher score of HADS in non-survival compared with surviving patients (P = 0.001). In addition, a higher serum level of cortisol was found in non-survival patients versus surviving patients (P=0.017).

###### 

Clinical characteristics of the patients

  **Variable**              **No. (%)/Mean±SD[\*](#TFN1){ref-type="table-fn"}**                                        
  ------------------------- ----------------------------------------------------- ------------- ------------- -------- ---------------------------------------
  Sex                       Male                                                  17(56.7)      15(57.7)      2(50)    0.773
  Female                    13(43.3)                                              11(42.3)      2(50)                  
  Age                       53.41±18.88                                           51.28±18.03   66.75±21.25   0.13     
  Medical History           Yes                                                   14(46.7)      10(38.5)      4(100)   0.022[\^](#TFN2){ref-type="table-fn"}
  No                        16(53.3)                                              16(61.5)      \-                     
  Serum level of cortisol   29.26±7.35                                            26.21±6.54    36.12±3.27    0.017    
  HADS score                15.63±7.27                                            13.07±6.26    24.75±5.25    0.001    

Standard deviation;

P\<0.05;

HADS: Hospital Anxiety And Depression Scale

Based on the two-way ANOVA test results, there was no statistically significant correlation between the outcome and comorbidity (P=0.278), and also no differences were found between the level of cortisol and HADS score (P=0.321). HADS score was found with a significant positive correlation with cortisol level (r; 0.842, P=0.004). There were no significant differences between sex and serum level of cortisol and HADS score (P=0.745 and P=0.912, respectively). Also, no significant correlation was observed between age and HADS score and cortisol level (P=0.684 and P=0.598, respectively).

4.. Discussion
==============

Our results revealed that although all participants had a mild to moderate presentation of COVID-19, patients with fatal outcome had higher serum cortisol levels and HADS score compared with the survived ones. This finding supports our primary hypothesis about the effect of stress and anxiety on the patient's vulnerability to the infection.

The COVID-19 pandemic has increased concerns of widespread panic and anxiety ([@B7]). Our lifestyle and habits are shifting dramatically, and COVID-19 pandemic has influenced all aspects of our lives ([@B9]). Unlike other viruses, like influenza viruses and other infections, media has overemphasized the COVID-19 as a particular hazard that further has increased fear, tension, and anxiety ([@B9]). The central nervous system, endocrine system, and immune system are closely linked ([@B14]). The inflammatory process may occur in response to psychological stress or other physical stressors by releasing neuropeptides or other inflammatory mediators ([@B2]).

Central neuropeptides, particularly CRH induce a systemic response to stress by triggering neuroendocrinological pathways, such as HPA, sympathetic nervous system, and angiotensin, resulting in releasing stress hormones (i.e. corticosteroids, catecholamines, glucagons, growth hormones, and renin) ([@B12]). This process along with stress-induced cytokines causes Acute-Phase Response (APR) and the activation of acute-phase proteins, which are important inflammation mediators ([@B2]). Norepinephrine in the central nervous system can also cause the APR by activating macrophages and releasing cytokines. The brain may activate the inflammatory process or inhibit it. The response to inflammation results in a subsequent psychological stress response. In addition, both stress and inflammation are mediated by the same neuropeptides (i.e. CRH). Cytokines evoked by either an inflammatory or stress response can cross similar somatosensory pathways to signal the brain ([@B2]). Repeated episodes of acute or chronic psycho-genic stress can cause chronic inflammatory changes in the brain and other organs.

Cohen et al. in their study noticed that psychological stress increased the risk of acute upper respiratory tract infections. They found that because of repeated stressful events, the failure of immune cells to control the inflammatory response increases the vulnerability to get common cold ([@B4]). In another study, Cohen et al. demonstrated that prolonged stress alters the efficacy of cortisol to modulate immune responses due to reduced sensitivity of tissues to the cortisol ([@B3]). A meta-analysis revealed that chronic stressful experiences could alter immune system responses, which might increase disease susceptibility. In this study, activation of the sympathetic nervous system via blockade of the beta-adrenergic endings, hormonal release following stressors, and behavioral factors were considered the possible mechanisms in immune dysregulation ([@B13]).

A recent paper showed that infection with COVID-19 caused the release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6 ([@B5]). Furthermore, psychosocial stressors in response to this pandemic might increase psychiatric problems. More than 50 % of patients with severe acute respiratory syndrome and middle east respiratory syndrome suffered from psychological distress ([@B11]). In line with the mentioned studies, our findings revealed that sever COVID-19 infection outcomes are more prominent at a higher level of serum cortisol and HADS score. Although the psychological aspects of COVID-19 are poorly understood, infected patients may experience anxiety, depression, etc. Consequently, the emotional problems may decrease immune response and recovery. In general, all types of psychological supports should be systematically implemented to enhance psychoneuro immunity against COVID-19.

The first limitation of this study was the limited number of participants. Larger studies are needed to find the exact relationship between stress and severity of the COVID-19 infection. The second drawback of our study was no measuring serial cortisol levels during the course of the disease, and this may affect our results. Last but not least, we did not enroll sever COVID-19 patients because they were hemodynamically unstable and could not complete the HADS; however, these cases might provide more clues to illuminate the effect of stress on the disease severity.
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